1. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen
- Author
-
Aline Van Pel, Nicolas van Baren, Christophe Lurquin, Thierry Connerotte, Thierry Boon, Takeshi Hanagiri, Sophie Lucas, Christophe Lonchay, Pierre Coulie, Marie Marchand, Didier Colau, Danièle Godelaine, and Vaios Karanikas
- Subjects
medicine.medical_treatment ,T cell ,Immunology ,T-cell receptor ,T lymphocyte ,Immunotherapy ,Biology ,Virology ,Immune system ,medicine.anatomical_structure ,Antigen ,Monoclonal ,medicine ,Immunology and Allergy ,Cytotoxic T cell - Abstract
'Cancer-germline' genes such as the MAGE gene family are expressed in many tumors and in male germline cells but not in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of metastatic melanoma patients. To establish whether there is a correlation between tumoral regressions and T-cell responses against the vaccine antigen, we evaluated the responses of patients vaccinated with a MAGE-3 antigenic peptide or a recombinant virus coding for the peptide. Blood lymphocytes were stimulated with antigenic peptide followed by detection with tetramer, T-cell cloning, and TCR analysis. In 4/9 regressor patients and in 1/14 progressors we found a low level, usually monoclonal cytolytic T lymphocyte response against the MAGE-3 peptide.
- Published
- 2002
- Full Text
- View/download PDF